Thermo Fisher Scientific has received the CE mark in the European Union for its diagnostic test to detect nucleic acid from SARS-CoV-2, the virus that causes COVID-19.
"The CE mark certification is an important step in combatting the outbreak of COVID-19 across Europe," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. "We are committed to fighting this disease and we will continue to work with regulatory authorities and customers around the world to expand the availability of diagnostic testing and stem the spread of the coronavirus."
The Thermo Fisher test, which uses Applied Biosystems TaqPath Assay and real-time PCR technology, is designed to provide patient results within four hours of a sample being received by a lab. The estimated time-to-result also includes time for sample preparation and instrument analysis.
This CE mark represents Thermo Fisher's assurance that its test complies with the European Union's In vitro Diagnostic Directive, which applies to products that are manufactured in or designed to be sold in the European Economic Area.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
Thermo Fisher Scientific received Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) for its COVID-19 test on March 13, 2020. This authorization was amended on March 24, 2020, to include additional instruments, such as the company's Applied Biosystems 7500 Fast Real-Time PCR System. This expands testing capabilities in the U.S. from approximately 1,000 instruments to more than 3,000 instruments on which Thermo Fisher's diagnostic test can be run. The expansion also includes manual sample extraction using the MagMax Viral/Pathogen Nucleic Acid Isolation Kit as well as Applied Biosystems COVID-19 Interpretive Software.
In addition to receiving the designated approvals in the U.S. and E.U., Thermo Fisher's diagnostic test has received the designated approvals in Canada, Singapore, India, Australia and New Zealand.